New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term ...

Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...

导读 2024年欧洲多发性硬化研究和治疗委员会大会（ECTRIMS ...

Discontinuing natalizumab or fingolimod (Gilenya) carried the highest risks. In France, an analysis of registry data revealed ...

Still in the game, but just barely, is Basel–based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing. Table 1 Selected MS therapies in ...

Progressive Multifocal Leukoencephalopathy (PML) is a severe, life-threatening condition that poses a particular risk for MS ...

Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly reduce brain volume loss compared with placebo. Indirect treatment comparisons reveal varying impacts of disease ...

PONVORY rose to the first choice position both in the 200 U.S. neurology study and the 400 multiple sclerosis patients study. The prescribers preferred ponesimod over siponimod, fingolimod and ...

The UK's National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to use Sanofi's Aubagio (teriflunomide) for adult patients with relapsing ...